Kabra drugs Limited has officially notified the BSE about an upcoming Board of Directors meeting scheduled for February 13, 2026. The pharmaceutical company will convene this important meeting to review and approve its quarterly financial performance for the third quarter of fiscal year 2026.

Board Meeting Details

The meeting is set to take place on Friday, February 13, 2026, at 5:00 PM at the company's Corporate Office located at No. 3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai – 600033. The primary agenda focuses on the consideration and approval of unaudited financial results for the quarter ended December 31, 2025.

Regulatory Compliance

The board meeting has been scheduled in accordance with Regulation 33 of SEBI (Listed Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to submit their quarterly financial results within specified timeframes and follow prescribed disclosure procedures.

The meeting agenda also includes provisions for considering any other matters that may arise with the permission of the Chairman during the proceedings.

Trading Window Restrictions

In compliance with insider trading regulations, Kabra Drugs Limited has implemented a trading window closure for all relevant parties. The restriction affects promoters, directors, designated employees, and concerned connected persons, preventing them from dealing in the company's shares until 48 hours after the announcement of the financial results.

This precautionary measure ensures adherence to SEBI's insider trading prevention guidelines and maintains market integrity during the period leading up to and immediately following the results announcement.

Company Information

The notification was signed by Nanjappan Aravind, Managing Director (DIN: 01895602), and submitted to the BSE on February 6, 2026. Kabra Drugs Limited, incorporated under CIN L02423MP1989PLC005438, maintains its registered office at 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh.

Kabra Drugs has received regulatory approval to acquire Vassmaan Automotive, marking a significant milestone in the pharmaceutical company's expansion strategy. The acquisition approval represents a strategic move by the company to diversify its business operations beyond its traditional pharmaceutical focus.

Acquisition Details

The regulatory approval for the Vassmaan Automotive acquisition enables Kabra Drugs to proceed with the transaction. This development signals the company's intent to expand into the automotive sector, potentially creating new revenue streams and business opportunities.

Channel Partner Expansion Strategy

Concurrent with the acquisition approval, Kabra Drugs has announced plans to establish a nationwide network of 200 channel partners. This expansion initiative demonstrates the company's commitment to strengthening its distribution capabilities and enhancing market penetration across India.

Business Implications

The dual announcements reflect Kabra Drugs' multi-pronged approach to business growth. The Vassmaan Automotive acquisition provides diversification opportunities, while the channel partner network expansion focuses on strengthening the company's core distribution infrastructure. These developments position the company for enhanced market presence and operational capabilities across different business segments.